Stock Analysis on Net

Medtronic PLC (NYSE:MDT)

$24.99

Return on Capital (ROC)

Microsoft Excel

Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Return on Invested Capital (ROIC)

Medtronic PLC, ROIC calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Invested capital2
Performance Ratio
ROIC3
Benchmarks
ROIC, Competitors4
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 NOPAT. See details »

2 Invested capital. See details »

3 2025 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Over the observed periods, the net operating profit after taxes (NOPAT) has exhibited notable fluctuations. Starting at 4,408 million USD in April 2020, the NOPAT decreased to 4,049 million USD in April 2021, indicating a decline. However, in April 2022, a recovery is evident with NOPAT rising to 4,888 million USD. Following this peak, a downward trajectory resumed, with values falling to 4,151 million USD in April 2023 and further declining to 3,736 million USD in April 2024. By April 2025, the NOPAT rebounded to 4,980 million USD, surpassing prior years' figures.

Invested capital data presents a relatively stable pattern with minor variations. Beginning at 71,146 million USD in April 2020, it slightly increased to 72,405 million USD in April 2021, then fell to 69,629 million USD in April 2022. It then experienced a moderate rise and fall, moving to 70,505 million USD in April 2023, decreasing again to 68,670 million USD in April 2024, and slightly increasing to 70,365 million USD by April 2025.

The return on invested capital (ROIC) percentage reflects the combined effects of the changes in NOPAT and invested capital. ROIC started at 6.2% in April 2020 and declined to 5.59% in April 2021, indicating reduced efficiency. This was followed by an increase to 7.02% in April 2022, suggesting improved profitability relative to invested capital. Subsequently, ROIC decreased to 5.89% in April 2023 and further to 5.44% in April 2024, paralleling the downward trend in NOPAT. The final data point in April 2025 shows an increase to 7.08%, the highest in the observed period, indicating enhanced capital utilization and profitability.

Summary of Trends:
The overall performance exhibits cyclical fluctuations, with NOPAT and ROIC demonstrating corresponding rises and declines. Invested capital maintains a narrower range of variation, suggesting stable investment levels. The peaks in ROIC in 2022 and 2025 correlate with higher NOPAT values and indicate periods of improved operational efficiency.
The most recent data point reflects a strong recovery in both NOPAT and ROIC, which may signal effective strategic initiatives or market conditions favoring improved returns on invested capital.

Decomposition of ROIC

Medtronic PLC, decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Apr 25, 2025 = × ×
Apr 26, 2024 = × ×
Apr 28, 2023 = × ×
Apr 29, 2022 = × ×
Apr 30, 2021 = × ×
Apr 24, 2020 = × ×

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


The financial data over the analyzed periods reveal various trends relating to profitability, efficiency, taxation, and returns on capital.

Operating Profit Margin (OPM)
The operating profit margin exhibits fluctuations throughout the periods. Initially, there is a decline from 17.88% in April 2020 to 16.48% in April 2021, followed by an increase reaching 19.63% in April 2023. Subsequently, a decrease to 17.14% is observed in April 2024, with a recovery to 19.14% projected for April 2025. This suggests variable operational efficiency with periods of improvement and contraction.
Turnover of Capital (TO)
The turnover of capital shows a gradual upward trend from 0.41 in April 2020 to 0.48 projected for April 2025. This steady increase indicates improving efficiency in utilizing capital assets to generate sales over time.
1 – Effective Cash Tax Rate (CTR)
The 1 - effective cash tax rate demonstrates a declining trend from 85.28% in April 2020 to 67.25% in April 2024, indicating a decrease in the effective rate at which cash earnings are taxed. There is a subsequent rise to 77.62% in the projection for April 2025, suggesting either changes in tax policy, profitability, or earnings composition influencing tax liabilities.
Return on Invested Capital (ROIC)
The return on invested capital reveals variability with an initial decrease from 6.2% in April 2020 to 5.59% in April 2021, then a recovery to 7.02% by April 2022. A dip follows to 5.44% in April 2024 before a projected increase again to 7.08% in April 2025. This pattern reflects changes in the company's ability to generate returns relative to its invested capital, showing periods of both enhanced and reduced capital effectiveness.

Overall, the data indicate fluctuations in profitability margins and returns on capital while showing consistent improvement in capital turnover. The effective cash tax rate trends suggest changing tax impacts across the years analyzed. The combination of these factors may reflect operational, strategic, and external influences impacting financial performance over the periods.


Operating Profit Margin (OPM)

Medtronic PLC, OPM calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
 
Net sales
Add: Increase (decrease) in deferred revenue
Adjusted net sales
Profitability Ratio
OPM3
Benchmarks
OPM, Competitors4
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2025 Calculation
OPM = 100 × NOPBT ÷ Adjusted net sales
= 100 × ÷ =

4 Click competitor name to see calculations.


Net Operating Profit Before Taxes (NOPBT)
The NOPBT exhibited fluctuations over the observed periods. Initially, there was a slight decline from 5,168 million USD in 2020 to 4,974 million USD in 2021. Following this, the figure rose to 6,074 million USD in 2022 and further accelerated to 6,130 million USD in 2023. A decrease occurred in 2024 to 5,556 million USD, before rising again to 6,416 million USD in 2025. Overall, the trend indicates variability with periods of growth interspersed with declines.
Adjusted Net Sales
The adjusted net sales demonstrated a consistent upward trajectory throughout the entire timeframe. Starting at 28,901 million USD in 2020, sales increased every year, reaching 33,530 million USD in 2025. The growth, though gradual, reflects steady expansion in revenue generation.
Operating Profit Margin (OPM)
The operating profit margin showed some variation over the period. From 17.88% in 2020, the margin decreased to 16.48% in 2021 before rising to a peak of 19.63% in 2023. A noticeable dip followed in 2024, dropping to 17.14%, with a recovery to 19.14% in 2025. The data suggests fluctuations in operational efficiency or cost structure impacts, with margins generally trending higher in the later years despite the interim variability.
Summary
The financial data reveals that while adjusted net sales grew steadily, operating profit margin and NOPBT experienced volatility. The profit margins and NOPBT indicate intermittent operational challenges or market factors affecting profitability, despite the consistent sales growth. The recovery patterns in 2025 for both profitability metrics suggest potential improvement in cost management or operational effectiveness.

Turnover of Capital (TO)

Medtronic PLC, TO calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Net sales
Add: Increase (decrease) in deferred revenue
Adjusted net sales
 
Invested capital1
Efficiency Ratio
TO2
Benchmarks
TO, Competitors3
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 Invested capital. See details »

2 2025 Calculation
TO = Adjusted net sales ÷ Invested capital
= ÷ =

3 Click competitor name to see calculations.


Adjusted net sales
The adjusted net sales show a consistent upward trend over the examined period. Beginning at 28,901 million US dollars in April 2020, sales increased each year with minor fluctuations, reaching 33,530 million US dollars by April 2025. This represents a total growth of approximately 16% over the six-year span. The only slight decline occurred between April 2022 and April 2023, where sales dipped from 31,717 million to 31,233 million US dollars, but the trend resumed upward thereafter.
Invested capital
Invested capital demonstrates some variability throughout the period, with an overall slight decline. Starting at 71,146 million US dollars in April 2020, the figure peaked at 72,405 million in April 2021, followed by a downward trend reaching a low of 68,670 million US dollars in April 2024. In the final period, April 2025, a slight recovery occurred, bringing invested capital back up to 70,365 million US dollars. This pattern suggests cautious capital management with a tendency toward optimization or divestment activities during the mid-period.
Turnover of capital (TO)
The turnover of capital ratio improved steadily over the years, increasing from 0.41 in April 2020 to 0.48 in April 2025. There was a peak at 0.46 in April 2022, followed by a minor decline in April 2023 to 0.44. However, after this, the ratio resumed its upward trend, reaching its highest level in the final reported period. This indicates enhanced efficiency in generating sales from invested capital, likely reflecting better asset utilization or productivity gains.
Overall Analysis
Over the period analyzed, sales growth outpaced fluctuations in invested capital, leading to improved capital turnover efficiency. The temporary declines in both adjusted net sales and turnover of capital around 2023 suggest a brief period of operational challenges or market conditions affecting performance. However, by 2025, these indicators show recovery and continued improvement. The slight reduction in invested capital from the initial peak may imply strategic capital restructuring to enhance returns. Collectively, these trends indicate progressive strengthening in operational efficiency and sales generation relative to capital invested.

Effective Cash Tax Rate (CTR)

Medtronic PLC, CTR calculation, comparison to benchmarks

Microsoft Excel
Apr 25, 2025 Apr 26, 2024 Apr 28, 2023 Apr 29, 2022 Apr 30, 2021 Apr 24, 2020
Selected Financial Data (US$ in millions)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
Tax Rate
CTR3
Benchmarks
CTR, Competitors4
Abbott Laboratories
CVS Health Corp.
Elevance Health Inc.
Intuitive Surgical Inc.
UnitedHealth Group Inc.

Based on: 10-K (reporting date: 2025-04-25), 10-K (reporting date: 2024-04-26), 10-K (reporting date: 2023-04-28), 10-K (reporting date: 2022-04-29), 10-K (reporting date: 2021-04-30), 10-K (reporting date: 2020-04-24).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2025 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =

4 Click competitor name to see calculations.


Cash Operating Taxes
The cash operating taxes show a general upward trend from 2020 to 2023, increasing from 761 million US dollars in 2020 to 1979 million US dollars in 2023. However, this trend reverses in the subsequent years, with a decrease to 1820 million in 2024 and further down to 1436 million in 2025. This indicates a peak in tax payments in 2023 followed by a decline.
Net Operating Profit Before Taxes (NOPBT)
The net operating profit before taxes exhibits some fluctuations across the years. It decreased slightly from 5168 million US dollars in 2020 to 4974 million in 2021, then rose significantly to 6074 million in 2022. It remained relatively stable in 2023 at 6130 million, dropped to 5556 million in 2024, and increased again to 6416 million in 2025. Overall, the figure shows resilience with a general upward tendency despite some volatility.
Effective Cash Tax Rate (CTR)
The effective cash tax rate percentage experienced a steady increase from 14.72% in 2020 to a high of 32.75% in 2024, more than doubling over this period. In 2025, the rate declined notably to 22.38%. This pattern suggests rising tax pressure during most of the observed period, followed by some relief or tax planning effectiveness in the latest year.
Insights
The data reflect a period of growth in operating profit before taxes, accompanied by rising taxes and an increasing effective cash tax rate until 2024, implying higher tax expenses relative to operating profits. The subsequent decrease in both cash operating taxes and tax rate in 2025, despite an increase in operating profit before taxes, suggests improved tax efficiency or changes in tax regulations. The volatility in NOPBT alongside changes in tax rates highlights the impact of operational performance and tax strategies on the company’s financial outcomes over the six-year period.